Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI vs XELIRI in advanced untreated colorectal carcinoma
2005-002181-11Phase 2Active
- Sponsor
- Oncology Institute of Bari
- Start
- Jul 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of irinotecan, capecitabine, fluorouracil and levoleucovorin in colorectal adenocarcinoma and colorectal cancer (CRC) (2 arms), sponsored by Oncology Institute of Bari. Primary endpoints: Objective response rate of XELIRI versus FOLFIRI and Safety of XELIRI versus FOLFIRI. Started Jul 2007; status: active.
02
Drugs
irinotecancapecitabinefluorouracillevoleucovorin
03
Conditions
colorectal adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on 2005-002181-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002181-11.